Login to Your Account



'Plumiaz' off the rose? Acorda CRL means more trials, unknown delay

By Randy Osborne
Staff Writer

Friday, May 2, 2014
Acorda Therapeutics Inc.'s second setback in less than a month came in the shape of a complete response letter (CRL) for the new drug application (NDA) related to Plumiaz (diazepam) for epileptic cluster seizures, and the company said the nasal spray version of the benzodiazepine therapy is unlikely to win approval this year.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription